Business
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China First patients dosed in CLYM116 Phase 1 healthy volunteer study Anticipating a data-rich 2026, with initial readouts from all ongoing budoprutug and CLYM116 studies Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., Jan. 08,
About this update from Climb Bio, Inc.
[{"type":"image","alt":"Climb Bio, Inc.","displaySize":"","headline":null,"caption":"Climb Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/upR1wQHp9TCZxvAhULaG8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c","width":300,"height":300}},"lazy":false},{"type":"text","content":"First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 ","length":107,"tagName":"p"},{"type":"text","content":"Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China","length":131,"tagName":"p"},{"type":"text","content":"First patients dosed in CLYM116 Phase 1 healthy volunteer study","length":63,"tagName":"p"},{"type":"text","content":"Anticipating a data-rich 2026, with initial readouts from all ongoing budoprutug and CLYM116 studies ","length":100,"tagName":"p"},{"type":"text","content":"Strong financial position with cash runway expected into 2028","length":61,"tagName":"p"},{"type":"text","content":"WELLESLEY HILLS, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced progress updates for its budoprutug and CLYM116 programs. The Company also highlighted its strategic priorities and key anticipated milestones for 2026 and refreshed its financial guidance.","length":402,"tagName":"p"},{"type":"text","content":"“Reflecting on 2025, we set out with ambitious goals, and I am proud of the substantial progress made across our clinical development and corporate objectives,” said Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer of Climb Bio. “We are now primed for a fulsome evaluation of budoprutug, our anti-CD19 monoclonal antibody, with the initiation of four clinical trials and the clearance of our China IND. We also rapidly advanced CLYM116, our anti-APRIL monoclonal antibody, into the clinic and dosed our first subjects in less than one year after announcing the in-licensing transaction. Across the portfolio we achieved 20 reg...